Page 10 - UHN-RR2020-6_Neat
P. 10
TECHNOLOGY TRANSFER
Bringing
Discoveries to Life
Breakthrough science and commercialization go hand-in-hand
in bringing benefits to patients
The path from early innovation in the lab 2019 SELECTED
to helping patients is often uphill and filled MILESTONES
with scientific and commercial challenges. A
critical step in making this leap is getting these TAKARA BIO INC. acquired an exclusive
innovations into the hands of companies with license for technology relating to UHN’s
next-generation immunotherapy (known
the resources required to carry them through as CAR T-cell therapy).
the research and regulatory journey. This step
is where our world-class researchers receive PHOTONAMIC GMBH & CO. KG
critical support from the commercialization acquired an oncology business from
team at UHN’s Technology Development & UHN spin-off MolecuLight Inc.
Commercialization team.
Toronto-based SQI DIAGNOSTIC
SYSTEMS INC. licensed a UHN lung
EXCELLENCE IN COMMERCIALIZATION biomarker technology that will enable the
UHN has had an exceptionally successful year in creation of a diagnostic lung platform to
research commercialization. Milestones include 20 assess patients with COVID-19.
new spin-off companies in the pipeline, nearly $1B
in cumulative (five-year) risk-capital investment Prostate cancer patients at UHN
become the first in world to be treated
from recent spin-offs and $37M in licensing with an AI-DRIVEN RADIATION
revenue cycling back to power the next wave TREATMENT PLANNING SYSTEM.
of breakthroughs. UHN has established itself The system was engineered at the
this year as one of the world’s top institutions in Princess Margaret Cancer Centre and
research commercialization. Techna Institute, and taken to market by
2020 RaySearch Laboratories.
8
